Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Authors

George R Blumenschein, The University of Texas MD Anderson Cancer Center
Siddhartha Devarakonda, Washington University School of Medicine in St. Louis
Ramaswamy Govindan, Washington University School of Medicine in St. Louis
et al

Journal

Journal for Immunotherapy of Cancer

Publication Date

1-1-2022

Volume

10

Issue

1

First Page

e003581

Document Type

Open Access Publication

DOI

10.1136/jitc-2021-003581

Rights and Permissions

Blumenschein GR, Devarakonda S, Johnson M, et alPhase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancerJournal for ImmunoTherapy of Cancer 2022;10:e003581. doi: 10.1136/jitc-2021-003581 https://jitc.bmj.com/content/10/1/e003581 Copyright 2021 The Authors This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Blumenschein, George R; Devarakonda, Siddhartha; Govindan, Ramaswamy; and et al, "Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer." Journal for Immunotherapy of Cancer. 10, 1. e003581 (2022).
https://digitalcommons.wustl.edu/oa_4/118